Investigate the Causality and Genetic Association Between Migraine and Parkinson’s Disease
Ming-Gang Deng,Xiuxiu Zhou,Fang Liu,Kai Wang,Lingli Luo,Min-Jie Zhang,Qianqian Feng,Jiewei Liu
DOI: https://doi.org/10.1101/2024.01.31.24302057
2024-01-01
Abstract:Background The relationship between migraine and Parkinson’s disease (PD) remains controversial. We intend to investigate the causal and genetic association between migraine and PD. Methods Data related to migraine [any migraine (AM), migraine without aura (MO), and migraine with aura (MA)] and PD were respectively obtained from the latest Genome-wide meta-analysis conducted by the International Headache Genetics Consortium and the International Parkinson’s Disease Genomics Consortium. Univariate Mendelian Randomization (UMR) and multivariate MR (MVMR) were conducted to estimate their bidirectional causality, and global/local genetic correlation and tissue expression analyses were utilized to assess their genetic associations. Results The UMR presented that AM (OR: 1.016, 95% CI: 0.908-1.135, p = 0.785), MO (OR: 0.944, 95% CI: 0.836-1.067, p = 0.358) and MA (OR: 1.006, 95% CI: 0.951, 1.064, p = 0.846) were unlikely to be associated with PD risk. Similarly, the reverse UMR analyses demonstrated that PD was unrelated to the risks of migraine and its subtypes. These null associations were supported by the MVMR when adjusted for coronary heart disease and hypertension. The global genetic correlation analyses presented that AM ( r g = -0.061, p = 0.127), MA ( r g = -0.047, p = 0.516), MO ( r g = -0.063, p = 0.492) were generally not related to PD, and the local genetic correlation analyses shown they were also uncorrelated in any region. Additionally, the tissue expression analyses found they had no shared tissues. Conclusion This study suggested no causality or association between migraine and PD from the genetic perspective. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study received no funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: GWAS summary statistics for migraine and subtypes were available at International Headache Genetics Consortium (), and Parkinson's disease associated data could be obtained from the International Parkinson's Disease Genomics Consortium (). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes GWAS summary statistics for migraine and subtypes were available at the International Headache Genetics Consortium (), and Parkinson's disease associated data could be obtained from the International Parkinson's Disease Genomics Consortium ().